Key result
High or moderate ANGPTL3 expression in glioblastoma patients was associated with a significantly shorter median overall survival of 6.3 months compared to 13.8 months for those with low or negative expression.
Population
57 patients with newly diagnosed glioblastoma who underwent tumor resection, median age 52 years, 32 male…
Design
Cohort, Two experienced observers reviewed the sections under microscope…
Authors
Loading...
Supports ANGPTL3 as a prognostic biomarker in glioblastoma; leaves open therapeutic targeting pending prospective validation.
Cohort (n=57)
Single-blind
No
Odds Ratio: 0.315 (95% CI 0.156–0.637)
Absolute Event Rate: 6.3% vs 13.8%
p-value: p=0.001
High/moderate expression of ANGPTL3 is an independent predictor of shorter overall survival in patients with glioblastoma.
WANG et al. (2015) conducted a cohort in Glioblastoma (n=57). High/moderate ANGPTL3 expression vs. Low/negative ANGPTL3 expression was evaluated on Overall survival (OR 0.315, 95% CI 0.156-0.637, p=0.001). High or moderate ANGPTL3 expression in glioblastoma patients was associated with a significantly shorter median overall survival of 6.3 months compared to 13.8 months for those with low or negative expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: